Figure 3.

![Figure 3.: Adverse effects and tolerability data from the oral minoxidil retrospective study in chronic telogen effluvium patients are reported, including the incidence of hypertrichosis and cardiovascular monitoring results.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676194/bin/f1000research-6-12721-g0002.jpg)

> Source: Eshini Perera et al. "Treatment of chronic telogen effluvium with oral minoxidil: A retrospective stud." *F1000Research*, 2017. PMID: [29167734](https://pubmed.ncbi.nlm.nih.gov/29167734/)

<figure>
  <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676194/bin/f1000research-6-12721-g0002.jpg" alt="Adverse effects and tolerability data from the oral minoxidil retrospective study in chronic telogen effluvium patients are reported, including the incidence of hypertrichosis and cardiovascular monitoring results." />
  <figcaption>Figure 3.. Adverse effects and tolerability data from the oral minoxidil retrospective study in chronic telogen effluvium patients are reported, including the incidence of hypertrichosis and cardiovascular monitoring results.<br>  Source: Eshini Perera et al. "Treatment of chronic telogen effluvium with oral minoxidil: A retrospective stud." <em>F1000Research</em>, 2017. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29167734/">29167734</a></figcaption>
</figure>